KRRO VS SLN Stock Comparison

Performance

KRRO
100/100

KRRO returned 192.66% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

SLN
10/100

SLN returned -31.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Earnings

KRRO
100/100

KRRO has missed earnings 0 times in the last 20 quarters.

SLN
100/100

SLN has missed earnings 1 times in the last 20 quarters.

Volatility

KRRO
100/100

KRRO has had a higher than average amount of volatility over the last 12 months giving it a score of 100 of 100.

SLN
47/100

SLN has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Sentiment

KRRO

"Sentiment" not found for KRRO

SLN
66/100

SLN had a bullish sentiment score of 65.84% across Twitter and StockTwits over the last 12 months. It had an average of 1.88 posts, 0.00 comments, and 0.75 likes per day.

Technicals

KRRO

"Technicals" not found for KRRO

SLN
71/100

SLN receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

Profit

KRRO

"Profit" not found for KRRO

SLN
10/100

Out of the last 13 quarters, SLN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Korro Bio, Inc. Common Stock Summary

Nasdaq / KRRO

Healthcare

Biotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Silence Therapeutics Plc American Depository Share Summary

Nasdaq / SLN

Healthcare

Biotechnology

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Power up your portfolio